A statement released earlier today by Wedbush about Pacira Pharma (NASDAQ:PCRX) bumps down the target price to $93.00
- Updated: October 19, 2016
Boasting a price of $34.65, Pacira Pharma (NASDAQ:PCRX) traded 0.00% even on the day. With the last stock price close down -19.91% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Pacira Pharma has recorded a 50-day average of $37.40 and a two hundred day average of $43.27. Volume of trade was down over the average, with 0 shares of PCRX changing hands under the typical 721,008
Stating a potential upside of 1.68%, Wedbush lowered the target price of Pacira Pharma (NASDAQ:PCRX) to $93.00
With a total market value of $0, Pacira Pharma has with a one year low of $31.08 and a one year high of $80.25 .
A total of 9 equity analysts have released a ratings update on PCRX. Five equity analysts rating the company a strong buy, four equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $82.22.
Brief Synopsis About Pacira Pharma (NASDAQ:PCRX)
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.